BioCryst Pharmaceuticals BCRX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$457.98M-757% | $263.86M+397% | -$8.78M+92.9% | -$35.71M+75.5% | -$53.47M+74.4% | ||
| $1.52M+19.5% | $1.39M+11.5% | $1.3M-4.1% | $1.28M-12.9% | $1.27M-18.3% | ||
| $79.73M+9.0% | $85.07M+30.0% | $82.61M+36.4% | $81.26M+46.2% | $73.13M+32.3% | ||
| $5.62M— | $1.64M— | $3.29M— | $3.12M— | —— | ||
| $30M— | $57.8M— | $42.84M— | —— | —— | ||
| $4.16M— | $7.83M— | $5.32M— | —— | —— | ||
| —— | —— | —— | —— | $0+100% | ||
| —— | —— | —— | —— | —— | ||
| $23.29M-29.1% | $36.81M+62.2% | $28.61M+55.7% | $31.91M— | $32.85M— | ||
| $313.1M— | $347.37M— | $50.2M— | —— | —— | ||
| $2.73M+164% | $2.47M+120% | $2.34M+133% | $1.06M-45.3% | $1.03M-54.0% | ||
| —— | —— | —— | —— | —— | ||
| $213.48M-6.2% | $262.24M-1.7% | $176.27M-54.1% | $144.56M-70.0% | $227.52M-49.9% | ||
| $401.88M+43.8% | $256.65M-19.9% | $265.65M-32.2% | $228.13M-54.7% | $279.48M-39.3% | ||
| —— | -$6.18M— | -$4.64M— | -$3.09M— | -$1.55M— | ||
| -$309.44M-680% | -$13.69M-125% | $87.59M+899% | $82.51M— | $53.38M— | ||
| —— | —— | —— | —— | —— | ||
| $26.2M— | $9.12M— | —— | —— | —— | ||
| $1.82M-0.7% | $1.99M+16.7% | $1.92M-23.6% | $1.96M+0.4% | $1.83M+17.7% | ||
| $8.68M+32.8% | $8.85M+17.4% | $5.93M-10.5% | $5.56M-12.6% | $6.54M+44.5% | ||
| —— | —— | —— | —— | —— | ||
| $62.09M— | -$349.93M— | -$135.99M— | —— | —— | ||
| —— | —— | —— | $1.36M+365% | -$145K-223% | ||
| $66.5M— | -$14.99M— | —— | —— | —— | ||
| $20.67M-40.2% | $23.74M-21.9% | $32.93M+30.5% | $37.02M+86.2% | $34.55M+72.9% | ||
| —— | —— | $2.6M+112% | $1.97M+66.2% | $1.42M-4.7% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$2.7M+72.1% | -$4.33M+62.3% | -$6M+50.7% | -$7.33M+42.4% | -$9.68M+19.8% | ||
| —— | —— | —— | —— | —— | ||
| —— | $17.55M— | $13.16M— | $8.77M— | $4.39M— | ||
| —— | —— | —— | —— | $0— | ||
| —— | $3.57M— | $2.67M— | $1.78M— | $891.5K— | ||
| $4.16M— | $7.83M— | $5.32M— | —— | —— | ||
| $74.51M— | $68.43M— | $78.09M— | $81.01M— | —— | ||
| $921K-41.3% | $1.06M-22.4% | $1.06M-31.7% | $2.39M+1,176% | $1.57M+735% | ||
| $52.94M— | $53.16M— | $53.34M— | $54.44M— | —— | ||
| —— | $0— | $0-100% | $0-100% | $0-100% | ||
| —— | -$6.18M— | -$4.64M— | -$3.09M— | -$1.55M— | ||
| $401.88M+43.8% | $256.65M-19.9% | $265.65M-32.2% | $228.13M-54.7% | $279.48M-39.3% | ||
| $1.82M-0.7% | $1.99M+16.7% | $1.92M-23.6% | $1.96M+0.4% | $1.83M+17.7% | ||
| —— | $15.5M— | $11.63M— | $7.75M— | $3.88M— | ||
| —— | —— | —— | —— | —— | ||
| $26.2M— | $9.12M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $23.36M— | $22.88M— | $16.41M— | $3.96M— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $1.2M-18.5% | ||
| —— | —— | —— | $912K— | —— | ||
| $310.37M— | $344.9M— | $47.86M— | —— | —— | ||
| $310.37M— | $344.9M— | $47.86M— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does BioCryst Pharmaceuticals generate?
- BioCryst Pharmaceuticals (BCRX) generated $313.1M in operating cash flow over the trailing twelve months.
- What is BioCryst Pharmaceuticals's free cash flow?
- After $2.7M of capital expenditures, BioCryst Pharmaceuticals's free cash flow was $310.4M over the trailing twelve months, up 448.8% year over year.
- Where does BioCryst Pharmaceuticals's cash flow data come from?
- Every line is extracted from BioCryst Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
